News and Trends 21 Jul 2022
Eiger receives European approval for progeria treatment
Eiger BioPharmaceuticals Inc., which focuses on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, has received marketing authorization from the European Commission (EC) for Zokinvy (lonafarnib), a therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL). Collectively known as progeria, […]